Tweets
Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment
⬆️ACR20 response compared to pbo
⬆️secondary endpoints
⭐️no new safety signals
Abs#453
#ACR21 #ACRBest @RheumNow
https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 9 months ago
Abs 457 #ACR21 @rheumnow
Exciting work by @alhkim and colleagues on SARS-CoV-2 Vaccination in CID patients
- Most (90%) developed Ab response but with reduced titers
- GC users including some low dose mounted low responses
- TNFi reduced in vitro neutralization of delta variant https://t.co/fJxnKmbccc
Akhil Sood MD @AkhilSoodMD ( View Tweet )
4 years 9 months ago
Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%reported a flare since the pandemic & 16% had COVID-19. 19% reported no changes to their care.76% reported a change in their mood& emotional health. Was your pts experience similar?
Olga Petryna @DrPetryna ( View Tweet )
4 years 9 months ago
2 year study of AxSpA pts in clinical remission who tapered TNFi.
⭐️52% successfully tapered to either 2/3, 1/2 or 1/3 dose
⭐️Baseline physician global score independent predictor of successful tapering
Abs#364
#ACR21
@RheumNow
https://t.co/9Kti5JGMYr https://t.co/y1Uj2dTABC
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 9 months ago
In a newly diagnosed SLE patient with class IV nephritis, already on HCQ, in addition to GC's, would you... #ACR21 #GreatDebate @rheumnow #LupusNephritis
TheDaoIndex @KDAO2011 ( View Tweet )
4 years 9 months ago
#ACR21 #ACRBest @Rheumnow
Abst #0452 Raychaudhuri et al.
TB-PET/CT indices ➡️ disease outcome measures in PsA
Identifies synovitis, enthesitis, dactylitis, nail matrix inflammation of PsA as compared to RA and OA
Future use as a diagnostic tool for early disease of PsA https://t.co/uLsAWEkboS
swethaann23 @swethaann23 ( View Tweet )
4 years 9 months ago
@ericdeinmd @RheumNow *TICOSPA
IMO, more an issue of poor tools for activity monitoring and insufficiently diverse toolbox. Works in RA as lots of choices and good activity measures. Until AxSpa has those, don’t see how we hope to meet “tight control”.
Ethan Craig @rheumecraig ( View Tweet )
4 years 9 months ago
@RheumNow #acr21 abst 195 prospective study of JAKi for refractory Still’s in 7 pts suggests JAKs can be useful as an add on but not in monotherapy : partial response 57%& failure in43%. No patient achieved complete remission. steroids could be decreased by63%~ https://t.co/rYHVReRHvL
Olga Petryna @DrPetryna ( View Tweet )
4 years 9 months ago
Irish registry of AS pts included 76 women who were pregnant
⭐️58% uncomplicated, 41.9% complicated, 11% multiple complications
⭐️frequency of miscarriage ⬆️
⭐️complications included C-section, preterm, NICU admission
#ACR21
@RheumNow
Abs#369 https://t.co/90dolEeTIw
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 9 months ago
#ClinicalPearl. During Q&A of abst#0457 Kim A, et al plenary at #ACR2021 #ACR21 Dr Kim said with 3rd #COVIDvaccination dose the pts who had little or no response to spike protein DID mount a response. 3rd dose in vulnerable pts works #ACRBest @RheumNow
Janet Pope @Janetbirdope ( View Tweet )
4 years 9 months ago
Secondary antiphospholipid syndrome (2APS) in SLE in Georgia Registry
👉12-14% of SLE pts
👉aCL 67%, LAC 51.5%, and aB2GP 7.7%
👉Inc rates of +dsDNA/Smith, livedo reticularis, serositis, & heme/renal/neuro d/o
👉⬇️rate in Black pts, but ⬆️thrombosis
#ACR21 Abs 0078 @RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 9 months ago
Self-monitoring app for AxSpA pts
⭐️adherence over 6 months poor 😔
⭐️high disease activity and older age related to ⬆️frequency of reporting
Abs#373
#ACR21
@RheumNow
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 9 months ago
